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Plant-based compounds have been in the spotlight in search of new and promising drugs. Flavokawain A, B and C
are naturally occurring chalcones that have been isolated from several medicinal plants; namely the piper
methysticum or commercially known as the kava-kava. Multiple researches have been done to evaluate the
bioactivities of these compounds. It has been shown that all three flavokawains may hold promising anti-cancer
effects. It has also been revealed that both flavokawain A and B are involved in the induction of cell cycle arrest in
several cancer cell lines. Nevertheless, flavokawain B was shown to be more effective in treating in vitro cancer cell
lines as compared to flavokawain A and C. Flavokawain B also exerts antinociceptive effects as well as anti-
inflammation properties. This mini-review attempts to discuss the biological properties of all the flavokawains that
have been reported.
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For centuries, mankind have always opted natural products
as an important companion in aiding illnesses and health-
related diseases [1]. This is generally because it is relatively
safe, cost-friendly and very diverse [2,3]. Kava-kava is a
plant scientifically known as piper methysticum and it be-
longs to the pepper family piperaceae [4]. It is physically
identified as a shrub and can be found in various parts of
the world, mainly in the south pacific region [4]. The use of
this plant in medicinal practices has been dated back to the
eighteenth century [4]. It was found that kava plant acts as
a diuretic and also as a mildly narcotic muscle relaxant
[4,5]. Kava-kava naturally has a strong odor and a pungent
taste, and is wildly cultivated among the Pacific Islanders [4].
A number of literatures have reported a variety of thera-
peutic properties in this plant species, such as anti-
inflammatory, anti-cancer, anti-oxidant and hepatoprotective
properties [4-6].
There are two major phytochemicals present within this
plant; the kavalactones and chalcones [5,7]. Chalcones are a
set of molecules derived from flavonoids and are also known
as benzalacetophenone or benzylidene acetophenone [8,9].
The basic molecular structure of chalcones includes two
aromatic rings linked by an unsaturated three carbon* Correspondence: noorjahan@biotech.upm.edu.my
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reproduction in any medium, provided the orbridge [8]. The sources of chalcones are mainly from
edible plants or can be readily synthesized by the Claisen-
Schmidt condensation method [9-11]. This class of
molecules has been found to possess several important bio-
activities such as anti-inflammatory, anti-oxidant, anti-
fungal, anti-angiogenic and anti-tumoral activities [11-15].
Chalcones in the kava plant can be recognized by their yel-
low appearance and are named flavokawains [5]. There are
three types of Flavokawains that have been identified;
Flavokawain A, Flavokawain B and Flavokawain C [16].
These compounds have similar backbones with different
side chains [16]. Flavokawain A is the largest chalcone con-
stituent with a 0.46% percentage in the kava extracts [16].
Flavokawain B follows this with 0.015% and Flavokawain C
with 0.012% [16]. Among the three flavokawains, only
flavokawain B has been extensively studied on. Table 1 sum-
marizes the physical properties of Flavokawain A, B and C
as well as depicting the molecular structure. Flavokawain B
is scientifically known as 6’-hydroxy-2’,4’-dimethoxychalcone
[17]. This compound was first reported to be found in the
roots of Piper methysticum [18]. It was later found in other
species as well such as Aniba riparia, P.triangularis var.
palloda and didymocarpus corchorijolia [17]. Table 2 reports
on the presence of the flavokawains in several plant species.. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 A summary of the properties of all three Flavokawains based on the findings of Dharmaratne et al., [16]
Properties Flavokawain A Flavokawain B Flavokawain C
Molecular weight 314.33 g mol−1 284.31 g mol − 1 300.31 g mol−1
Molecular formula C18H18O5 C17H16O4 C17H16O5
Molecular structure
Physical appearance Yellow crystalline Yellow crystalline Yellow crystalline
Melting point 111-115°C 96-98°C 185-188°C
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Anti-inflammatory activity
The anti-inflammation activity of flavokawain A was
examined by Kwon et al. in 2013 [23]. Kwon et al.
conducted the research by inducing inflammation via
LPS-stimulated RAW 264.7 cells [23]. Flavokawain A sig-
nificantly suppressed the expression of iNOS and COX2.
This is most likely accomplished by the inhibition of NF-
ΚB pathway [23]. The halted production of these proteins
also subdued the expression of NO and PGE2 [23].
Upstream of iNOS and COX2, the activation of JNK and
p38 MAPK were also inhibited. Additionally, flavokawain
A inhibited the activation of AP-1 pathway upon the in-
duction with LPS [23]. Moreover, flavokawain A also
suppressed the expression of several pro-inflammatory cy-
tokines including IL-6, IL-1B and TNF- α [23].
Anti-cancer activity
Flavokawain A has been found to possess potential anti-
cancer properties. For instance, in a research conducted
by Tang et al. in 2008 [24], flavokawain A affected the cell
cycle regulation of a p53-wild-type bladder cancer cell line
(RT4). It was found that flavokawain A increased the
amount of p21 and p27 cell cycle regulatory proteins and




Alpinia pricei Hayata Flavokawain B [19]
Alpinia pricei rhizome [20]
Kava
Piper methysticum Flavokawain A [17]
P. triangularis var. pallida Flavokawain B [17]
Didymocarpus corchorijolia Flavokawain C [17]
Aniba riparia [21]
Annonaceae
Goniothalamus gardneri Flavokawain A [22]that in p53-mutant-type T24 cells, flavokawain A induced
a G2/M arrest instead [24]. Tang et al. [24] suggested that
the molecular mechanism underlying this occurrence was
through the reduction of inhibitory kinases, Myt1 and
Wee1 [24]. In a similar study conducted by Zi et al. in 2005,
[7] flavokawain A was shown to execute a mitochondria-
dependent apoptosis in T24 cells. Flavokawain A was proven
to induce apoptosis in T24 bladder cancer cell line through
the dependency on Bax, a mitochondrial protein [7]. The
study reported that this compound also cleaved caspase 3,
caspase 9 and poly- (ADP-ribose) polymerase to induce
apoptosis in a dose-dependent manner [7]. This notion was
also supported when there were changes in the mitochon-
drial membrane potential that lead to the release of cyto-
chrome C [7]. Moreover, the ratio of Bax/Bcl-xl changed
upon the treatment of flavokawain A. The ratio increased
gradually until 650% in a time dependent manner [25].
Expectantly, this compound also decreased the level
of X-linked inhibitor of apoptosis (XIAP) and survivin
in T24 cells [25]. In an in-vivo xenograft model of
bladder cancer, flavokawain A significantly decreased
the tumor volume by approximately 57% [7].
Flavokawain B
Anti-inflammatory activity
The anti-inflammatory property of flavokawain B was
assessed by a study conducted by Lin et al. in 2009 [25].
The study tested this compound against LPS-induced RAW
264.7 cells [25]. It was found that flavokawain B had an im-
pressive effect in inhibiting nitric oxide production with an
IC50 of 9.8 μM, lesser than the positive control used,
curcumin [25]. Additionally, flavokawain B also inhibited
PGE2 in a dose-dependent manner [25]. Similarly, these ef-
fects were also seen in the inhibition of TNF-α, a cytokine
that is regularly involved in inflammation [25]. Furthermore,
further analysis on the alteration of iNOS and COX-2 pro-
tein were also measured. Flavokawain B was found to inhibit
the expression of both proteins depending on the concen-
tration. To further clarify the activated inflammatory path-
way upon the exposure of flavokawain B, NF- κB – related
proteins were tested [25]. Results showed that flavokawain B
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IkBα and inhibiting the activation of Iκκ [25]. Furthermore,
flavokawain B has been found to significantly inhibit COX-I
at 100 μg/ml, as well as COX-II enzyme [26].
Antinociceptive activity
Two studies by Mohamad et al. [27,28] proved that
flavokawain B has the potential to be developed into an
antinocicepetive drug. Through the acetic acid-induced ab-
dominal writhing test, it was discovered that at 128.6 mg/kg,
the positive control, acetylsalicylic acid exhibited the same
effect as flavokawain B when the dose was 10 mg/kg [27].
This indicates that flavokawain B was 68 fold more effec-
tive than acetylsalicylic acid [27]. This indictment also
suggests that the activity of flavokawain B may involve inhib-
ition of cyclooxygenases or lipooxygenases [27]. Moreover,
flavokawain B was more effective when it is being adminis-
tered intraperitoneally rather than orally by seven-fold [27].
To further elucidate the antinociceptive activity of
flavokawain B, Mohamad et al. conducted another study and
suggested that flavokawain B operates via the activation of the
NO-cGMP-PKC-ATP-sensitive K+ channels pathway [28].
Anti-cancer properties
Researches in treating cancer, and better yet, preventing this
disease has been significantly expanding. To date, the num-
ber of treatments varies and ranges from radiotherapy to
herbal, alternative medicine. The most opted way of treating
neoplasm is by administering drugs to the patient [29].
Flavokawain B has been found to be cytotoxic towards sev-
eral important cancer cell lines. The most recent study was
done by Ji et al. whom discovered the cytotoxic effects of
flavokawain B on osteosarcoma cell lines [30]. This study re-
vealed that flavokawain B exuded an apoptotic effect on
these osteosarcoma cancer cell lines via the activation of
caspase 3/7, caspase 8 and caspase 9 [30]. Furthermore,
flavokawain B was also shown to down-regulate several
anti-apoptotic proteins such as Bcl-2 and survivin [30]. Con-
sequently, this compound also up-regulated various pro-
apoptotic proteins including Bax, Fas and Puma [30]. More-
over, it was also observed, that flavokawain B induced a
G2/M arrest by increasing Myt1 levels and concomitantly
decreasing cdc2, cyclin B1 and cdc25c levels [30]. Interes-
tingly, it has also been noted that flavokawain B decreased
the migration and invasion ability of osteosarcoma cell lines
[30]. This attribute is a favorable property especially in
treating highly metastastic cancer cells.
Oral carcinoma is becoming more prevalent, especially
in the South and Pacific Asia region [31]. Flavokawain B
was shown to be cytotoxic towards the HSC-3, A-2058,
Cal-27 and A-549 cell lines [19]. In normal gingival fibro-
blast cell line interestingly, flavokawain B showed very
minimal cytotoxic effect [19]. Additionally, this compound
was proven to cause a cell cycle arrest in the HSC-3 cellline. The number of cells in the G2/M phase increased in
comparison with the control upon 12 hours of post-
treatment [19]. The arrest in the G2/M phase may involve
the inhibition of several important cyclin/cdk complexes.
Hseu et al. in 2012, proposed that flavokawain B was in-
volved in the inactivation of Cdc2, Cdc25c, Cyclin A and
Cyclin B1 in HSC-3 cell line. Furthermore, it was also
proven that this compound caused a shift in the mito-
chondrial membrane permeabilization potential, indicat-
ing that treated cells had a compromised mitochondria
[19]. Furthermore, mitochondrial-related proteins were
also regulated upon the induction of flavokawain B. Cyto-
chrome c for instance, was found to be upregulated in the
cytosol in a dose-dependent manner [19]. Moreover,
flavokawain B also induced apoptosis in human oral ade-
noid cystic cancer, ACC-2 [32]. Flavokawain B was shown
to induce G2/M arrest and induce the release of cyto-
chrome c [32]. This subsequently lead to the activation of
caspase 3 and the cleavage of the PARP enzyme [32].
Apart from HSC-3 cell line, flavokawain B can also be cyto-
toxic towards synovial sarcoma cell lines [33]. A study by
Sakai et al. in 2011 [33], used two synovial sarcoma lines,
SYO-1 and HS-SY-II to test for the cytotoxic activity of
flavokawain B. Upon treatment, both the SYO-1 and HS-SY-
II cell lines exhibited pro-apoptotic morphology such as cell
membrane blebbing and cell shrinkage [33]. It is suggested
that flavokawain B impeded cell growth in a concentration-
dependent manner [33]. The increment of expression of
caspase 8, 9 and 3/7 implied that flavokawain B activates the
death-receptor and mitochondrial-mediated apoptotic me-
chanism [33]. Moreover in flavokawain B-induced SYO-I and
HS-SY-II cells, the expressions of death receptor 5, Bim and
Puma were up-regulated while the expression of survivin, an
anti-apoptotic protein was down-regulated [33]. Another pro-
apoptotic protein, Bak was also up-regulated when treated
with flavokawain B at a concentration of 7.5 μg/ml [33].
Flavokawain B was also found to induce apoptosis in
several prostate cancer cell lines while having insignificant
effects on the normal prostate cell line [34]. This predica-
ment is based on the morphology changes that occur in
flavokawain B-treated cells which include, cell shrinkage,
cell blebbing, nuclear fragmentation and condensation
[34]. Additionally, Tang et al. [34] also discovered that
flavokawain B induced apoptosis by the activation of sev-
eral caspases in DU145 and PC-3 cell lines [34]. The cleav-
age of PARP, a pro-apoptotic protein was also seen in
DU145 and PC-3 cell lines when induced with flavokawain
B [34]. Besides, this compound increased the expression
of several pro-apoptotic proteins, Bim, Bax and Puma, and
conversely decreased the expression, of XIAP and survivin,
both are anti-apoptotic proteins [34]. Interestingly, Li et al.,
2012, conducted another study regarding the effects of
flavokawain B on several other prostate cancer-related cell
lines such as LAPC4, C4-2B, LNCaP, 22RV1 and WPMY-1
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AR protein expression in all cell lines [35]. Additionally,
flavokawain B also downregulated the expression of the
AR target protein, PSA [35]. At the transcription level,
flavokawain B significantly decreased the mRNA expression
of AR, PSA and TMPSS2 in LNCaP and C4-2B cell lines
[35]. It wasl aslo deiscovered that, flavokawain B decreased
the level of AR through the downregulation of the SP1 pro-
tein expression [35].
Additionally, flavokawain B was also found to inhibit
HCT116, a colon cancer cell line [6]. Kuo et al. [6], reported
that flavokawain B induced an anti-proliferation state of
HCT116 cells when treated with 5–50 μM of the com-
pound. This observation was supported when the level of
cleaved-PARP protein was noticeable at 50 μM of treatment
[6]. The mitochondrial-induced apoptosis pathway was pro-
posed because of the loss of the mitochondrial potential,
release of cytochrome c and translocation of Bak [6].
Kuo et al. also found that GADD153, a marker for endo-
plasmic reticulum stress, was significantly upregulated.
This further confirms the mitochondria-mediated apop-
tosis [6]. Additionally, BCL-2, an anti-apoptotic protein,
downstream of GADD153 was downregulated when in-
duced with flavokawain B [6]. Furthermore, it was discov-
ered that flavokawain B increased the level of ROS and
p38, both contributing to the execution of apoptosis [6].
Likewise to Hseu et al. 2012, flavokawain B was also
found to induce a G2/M arrest in HCT116 cells [6].
Another study was conducted by An et al. in 2012,
addressed the anti-neoplastic activity of flavokawain B on
non-small cell lung cancer, H460 cells. The findings were
similar to the other studies conducted; flavokawain B in-
duced a mitochondrial-dependent apoptosis pathway [36].
This study showed that flavokawain B induced the release of
cytochrome c and deregulated the BcL-xL/Bax ratio [36].
Likewise to other studies, it was also proven that flavokawain
B down-regulated the anti-apoptotic proteins, XIAP and
survivin [36]. Additionally, it was found that flavokawain B
activated the MAPK pathway and subsequently the JNK-
mediated apoptotic pathway [36]. The effects of flavokawain
B on uterine leiomyosarcoma cell lines were tested by
Eskander et al. 2012. Similar to other studies, this study also
concluded that flavokawain B induced a G2/M arrest in
treated cells [37]. Furthermore, also in accordance with other
findings, flavokawain B up-regulated several pro-apoptotic
proteins such as death receptor 5, Puma and Bim, and also
down-regulated IAP and survivin [37].
Another recent study on the anti-cancer mechanism of
flavokawain B was conducted on squamous carcinoma cells,
KB cells [38]. Lin et al. in 2012, designed the study to deter-
mine the apoptotic, anti-proliferative activity and anti-
metastatic activity of flavokawain B on KB cells [38]. This
study also prove that flavokawain B induced a G2/M arrest
as evidenced by the reduction of cyclin A, cyclin B1, cdc2,cdc25c and increment of p53, p21 and wee1 [38]. The in-
duction of apoptosis on the other hand, was substantiated
by the activation of caspase 3,-8 and −9 as well as the clea-
vage of PARP [38]. Additionally, the levels of Bid and Bax
were increased coupled with the decrement of Bcl2 [38]. As
an anti-metastatic drug, flavokawain B remains promising as
it inhibited the expression of matrix-metalloproteinase 9
and urokinase plasminogen activator [38].
Besides in vitro, analyses on in vivo model were also
conducted by some studies [7,24,34]. A research by Tang
et al. tested the compound flavokawain B on nude mice in-
duced with DU145 cells. Expectantly, flavokawain B signifi-
cantly reduces the growth of these tumors by approximately
67% [34]. The level of Bim was found to be increased in
tumor lysates as compared to the untreated control [34].
Additionally, it was reported that there were no necropsy or
growth irregularities in the treated mice [34]. The anti cancer
in vivo effects of flavokawain B in KB xenograft models was
also tested [38]. Flavokawain B significantly reduced the
growth of the tumor as proven by the augmentation of
apoptotic DNA fragmentation [38]. Li et al. 2012, also stu-
died the interaction of flavokawain B on two patient-derived
prostate cancer xenografts in mice. The study found that
flavokawain B inhibited the growth of the tumor, reduced
the expression of AR as well as the levels of serum PSA [35].Other properties
Additionally, a research conducted by Feroz et al. studied the
interaction between flavokawin B and human serum albumin
[39]. The efficacy of the pharmacokinetics and pharmaco-
dynamics of a certain drug once it is inside the body is greatly
dependent on its interaction with plasma protein [39]. It is
well known that human serum albumin is a major player
in the transport of various ligands [39]. As expected,
flavokawain B was found to interact with human serum
albumin similarly to other flavonoids [39]. The binding es-
sentially comprises of hydrophobic interactions including
hydrogen bonding [39].Flavokawain C
Anti-cancer properties
Flavokawain C has been tested for its anti-cancer activities
against several bladder cancer cell lines [7]. The results
showed that flavokawain C induced an anti-proliferative
and an apoptotic state in these cell lines (T24, RT4 and EJ
cells) [7]. The IC50 of flavokawain C was promising as it
was relatively low (≤17 μM) [7]. Additionally, in two liver
cancer cell lines, L02 and HepG2, flavokawain C had a
substantially higher IC50 value (<60 μM) as compared to
the bladder cancer cell lines [40]. Nevertheless, further
analysis should be done to determine flavokawain C’s ef-
fects on normal cell lines.
Table 3 A summary of in vitro IC50 of Flavokawain A, B, C
in selected cancer cell lines
Flavokawain Cancer cell lines IC50 μM





Flavokawain B KB 20.05 ± 0.4
MCF-7 49.30 ± 1.8
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Through the findings of these studies, it can be suggested that
the anti-cancer action of flavokawain A is dependent on the
p53 status of the cancer cells. In the p53-wild type cancer
cells, flavokawain A is more likely to induce a G1 arrest in-
stead of a G2/M arrest in the p53-mutant cells. This state-
ment needs further proof to definitively conclude whether the
effect of flavokawain A is p53-dependent. Majority of the
studies conducted suggest that flavokawain B induces apop-
tosis both through the mitochondria-dependent pathway and
death-receptor pathway. Additionally, flavokawain B induces
G2/M arrest in most of the tested cell lines regardless
of the p53 status, unlike flavokawain A.
Since inflammation plays a major role in cancer progres-
sion, the anti-inflammatory effects of flavokawain A and B
should also be considered in elucidating its anti-cancer ac-
tivity. Flavokawain A and B inhibited the NF-κB pathway
and subsequently the JNK pathway. This suggest that
flavokawain A and B may also induce TNF-α-mediated
apoptosis [41]. The JNK pathway may also induce changes
in the mitochondria membrane potential [41,42]. This may
consequently lead to the release of cytochrome c and the
activation of caspases as observed in several studies [42].
Additionally, most of the studies revealed that there were
changes in the expression level of some mitochondrial-
related proteins, especially in the BCL2 family [30,33]. A
summary of the IC50 values of all three flavokawains in vari-
ous cell lines is provided in Table 3.22RV1 16.6
C4-2B 2.2
L-02 35.15 ± 2.56









Flavokawain C RT4 ~1.5-17
EJ ~8.33
L-02 57.04 ± 2.32
HepG2 59.48 ± 2.72
[6,7,19,24,25,33-35,38,40].Structure-activity relationship
All three flavokawains share a similar backbone bearing a
2’-hydroxy-4’, 6’-dimethoxychalcone [16]. The differences
lay in the R-4 position; flavokawain A contains a methoxy
group, flavokawain B only retains the designated hydrogen,
and flavokawain C with an extra hydroxyl group [16]. All
three molecules have the same physical structure except
for the melting point. In terms of bioactivity, based on
evidenced studies, both flavokawain A and flavokawain B
possess anti-inflammatory activity at almost similar con-
centrations [23,25]. The difference in the methoxy group
did not account for a substantial difference. The difference
in the IC50 of the flavokawains against three bladder can-
cer cell lines (T24, RT4, and EJ) and two liver cancer cell
lines (HepG2 and LO2) can be assessed to determine the
structure-activity relationship. The IC50 of flavokawain A
is slightly higher than the other two flavokawains in the
bladder cancer cell lines [7,40]. In the liver cancer cell lines
however, flavokawain A did not have an IC50 value, unlike
flavokawain B and C [40]. This is probably due to differ-
ence in the side chain. Bearing a methoxy group could
introduce steric hindrance and possibly explain the de-
crease in anti-cancer activity as compared to the other two
flavokawains [43].Toxicity
The kava plant has long been used in traditional practices
as an herbal tonic [4]. Nevertheless, there have been re-
ports claiming that the flavokawains may cause hepatoto-
xicity [44]. This is due to the cases that kava extracts may
cause several hepatic failures in consumers [45]. A study
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hepatotoxin in the kava extracts [46]. However, there have
been no reports on any liver damages when in vivo studies
were done [34]. Teschke et al. [44] has asserted that the
liver toxicity cases were only reported in the South pacific
region and this is probably due to the tropical humidity and
temperature. The kava plants may have been contaminated
by mould hepatotoxins instead [47]. Teschke et al. [44] also
stated that the level of flavokawain B in the kava extracts is
too low to be causing liver injury [47]. There is a need to
determine the acute and subchronic toxicity in vivo to fur-
ther clarify whether the flavokawains are safe to be con-
sumed and developed into the pharmaceutical line.
Conclusion
The Flavokawains are becoming more favorable in becom-
ing anti-cancer agents candidates. Most of the studies re-
veal that the flavokawains induce apoptosis instead of
necrosis in cancer cell lines. This is generally a promising
factor if it is further developed into the commercial line.
Flavokawain A and flavokawain B has been found to inter-
act with several important molecular proteins and signal-
ing pathways. Additonally, the flavokawains (A and B)
were shown to inhibit the NF- κB pathway and the inflam-
matory process in vitro. The flavokawains also exhibited
anti-cancer activities in xenograft models. Even though
there have been reports regarding the liver toxicity in-
duced by flavokawain B, this assertion has been refuted.
The flavokawains still remain a potential group of mole-
cules that can be used as anti-cancer agents. How-
ever, further in depth studies must be done in order to
fully understand the mechanism underlying flavokawain’s
potent activity.
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